At Lupin, patient centricity is about building meaningful, accessible and holistic healthcare solutions. Through our adjacencies, we are addressing unmet needs across diagnosis, prevention, treatment, and rehabilitation.
Our focused services reflect our commitment to making healthcare more inclusive, personalized, and impactful. Discover how these businesses are transforming care and enhancing lives.
LupinLife is our consumer healthcare division, focused on delivering science-led, trusted wellness solutions that are aligned with India’s evolving healthcare needs. As a strategic arm of Lupin’s prescription business, LupinLife represents a strong pivot towards the holistic over-the-counter (OTC) medication segment.
Since its inception in 2017, LupinLife has built a diversified portfolio across gastro care, health supplements, women’s health, and pain management. Its flagship brand Softovac leads the bulk laxatives category with a 42% market share and has doubled in size over 5 years, driven by innovations like Softovac Liquid Fibre.
In the children’s health category, Aptivate has strengthened emotional engagement with families through high-impact activations. Our OTC segment accelerates portfolio innovation and unlocks sharper consumer focus for sustainable future growth.
Lupin Diagnostics plays a pivotal role in India’s shift toward preventive and personalized healthcare by delivering high-quality, accessible diagnostic services. Launched in 2021, the business has rapidly built a pan-India presence with 44 processing labs across 250+ cities, including Tier 3 and Tier 4 towns.
Serving 150,000+ patients every month, Lupin Diagnostics has achieved strong revenue growth in just three years. Quality is central to our operations, with NABL-accredited greenfield labs and a 450,000 sq ft state-of-the-art National Reference Laboratory in Navi Mumbai that’s equipped with advanced genomic and molecular technologies.
With 750+ collection centers, 200+ trained field executives, and a robust home-collection network, Lupin Diagnostics ensures last-mile access and reliable results.
Lupin Digital Health is redefining chronic disease management through clinically validated digital therapies, with a strong focus on cardiovascular care. Its flagship platform, LYFE, supports patients with heart diseases through remote monitoring, behavioral support, and digital care coaches, reaching 380+ districts across India.
The platform partners with insurers, hospitals, and surgical care providers, becoming an integral part of patient journeys. Expanding beyond treatment, Lupin Digital Health has launched a prevention-focused platform for individuals at risk of cardiometabolic diseases including hypertension, type 2 diabetes, dyslipidemia, and obesity.
Backed by global collaborations, including with the American College of Cardiology, and multiple peer-reviewed publications, the platform combines scientific rigor with user-centric design. With key regulatory approvals and global quality certifications, the business represents a scalable, human-first approach to digital care.
Atharv Ability exemplifies Lupin’s commitment to neurological rehabilitation, an area that is often overlooked in India. Based in Mumbai, Atharv Ability’s state-of-the-art neuro-rehabilitation center caters to a wide spectrum of conditions including stroke, brain or spine injury, Parkinson’s disease, cerebral palsy, and multiple sclerosis. Its integrated care model includes neurophysiotherapy, robotic rehabilitation, speech and occupational therapy, cognitive and pediatric neurological rehabilitation, and aqua therapy, for adults and children.
As of date, 2,800+ patients have been treated, 40,000 therapy sessions have been delivered, and approximately 40% improvement has been demonstrated in functional recovery and quality of life across patient cohorts.
Atharv Ability has now extended its operations in Hyderabad, setting new benchmarks for accessible high-quality neurorehabilitation in India.
Lupin Life Sciences (LLS) is Lupin’s trade generics business unit, created as our wholly owned subsidiary. The intent of this unit is to sharpen focus in a fast-growing and high-impact segment. With a portfolio of 350+ products spanning across pain management, gastrointestinal care, anti-infectives, respiratory care, dermatology, and multivitamins. LLS takes a step forward in Lupin’s commitment to make affordable healthcare accessible to all.
The business has undergone strategic transformation by streamlining its operations and expanding its national footprint. LLS efforts are shifting and directed towards demand generation at the last mile, with a strong field force, and deeper chemist engagement.
LLS enhances patient access to quality medicines. Its renewed approach positions it as a market shaper in India’s evolving trade generics landscape.
By combining the power of science, technology and empathy, Lupin is continuing to create integrated care models and services that serve as touchpoints across various stages of the patient journey.
